Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
18.55
-0.35 (-1.85%)
At close: Dec 18, 2025, 4:00 PM EST
18.55
0.00 (0.00%)
After-hours: Dec 18, 2025, 4:03 PM EST
Dyne Therapeutics Employees
Dyne Therapeutics had 191 employees as of December 31, 2024. The number of employees increased by 50 or 35.46% compared to the previous year.
Employees
191
Change (1Y)
50
Growth (1Y)
35.46%
Revenue / Employee
n/a
Profits / Employee
-$2,218,853
Market Cap
2.65B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 191 | 50 | 35.46% |
| Dec 31, 2023 | 141 | 22 | 18.49% |
| Dec 31, 2022 | 119 | 26 | 27.96% |
| Dec 31, 2021 | 93 | 46 | 97.87% |
| Dec 31, 2020 | 47 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DYN News
- 7 days ago - Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - GlobeNewsWire
- 8 days ago - Dyne Therapeutics: Why The $350M Public Offering Was Critical - Seeking Alpha
- 8 days ago - Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock - GlobeNewsWire
- 10 days ago - Dyne Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 10 days ago - Dyne Therapeutics, Inc. (DYN) Discusses Positive Topline Results From DELIVER Registrational Expansion Cohort in Duchenne Muscular Dystrophy Transcript - Seeking Alpha
- 10 days ago - Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) - GlobeNewsWire
- 11 days ago - Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET - GlobeNewsWire
- 6 weeks ago - Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire